Skip to main content
OpenTrials
Completed

NCT Number: NCT03066505

A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With ADHD

This pilot study is a randomized, double-blind, sham-controlled study designed to evaluate the efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in college students with ADHD. A total of 40 subjects will be treated.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

USC Neurorestoration Center

Los Angeles, California, 90033, United States

About this study

This pilot study is a randomized, double-blind, sham-controlled study designed to evaluate the efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in college students with ADHD. A total of 40 subjects will be treated.

Twenty (20) subjects will receive active treatment with MeRT and the other 20 with sham. Subjects in each study group will be treated 30 min a day, 5 days a week for 4 weeks. This is known as Phase 1. During this study period, subjects and clinicians will be blind to treatment condition.

Subjects will be recruited from a flyer describing the study. The flyer will be posted at the Kortschak Center for Learning and Creativity, the McKay Center, and through Student Counseling Services in the Engemann Student Health Center. In addition, students who have been diagnosed with ADHD and have been seen at one of these facilities for ADHD may be provided contact information for the study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Subjects must meet all of the following inclusion criteria to qualify for enrollment into the study:

  • College student 18-25 years of age
  • Diagnosed with ADHD using the standardized clinical interview and supported by the Pearson Quotient ADHD System and Conners Adult ADHD Rating Scales (CAARS)
  • Willing and able to adhere to the treatment schedule and all required study visits

Exclusion criteria

Subjects will be excluded from study participation if one of the following exclusion criteria applies:

  • Pregnant or trying to become pregnant; negative urine pregnancy test at screening will be required of females of child-bearing potential
  • Any antipsychotic or anticonvulsant medication.
  • Any type of rTMS treatment within 3 months prior to the screening visit
  • Intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, stents, or electrodes) or any other metal object within or near the head, excluding the mouth, which cannot be safely removed
  • Any condition which in the judgment of the investigator would prevent the subject from completing the study
  • Any seizure history within the past 10 years
  • EEG abnormalities including indications of risk of seizure, i.e., abnormal focal or general slowing in spikes during the EEG recording
  • Unstable medical conditions such as uncontrolled endocrine, hepatic, cardiac, pulmonary and/or renal disorders.

Treatment and study plan

Active MeRT Treatment

Device

A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.

Other names: rTMS Active Stimulator

Sham MeRT Treatment

Device

A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.

Other names: rTMS Sham Stimulator

Primary outcomes

  1. Pearson Quotient ADHD System

    Time frame: Four weeks.

    Changes in Pearson Quotient ADHD System; arithmetic changes in Pearson Quotient ADHD System score between time points at baseline and end of week 4.

  2. Conners Adult ADHD Rating Scales (CAARS)

    Time frame: Four weeks.

    Changes in Conners Adult ADHD Rating Scales (CAARS) ; arithmetic changes in Conners Adult ADHD Rating Scales (CAARS) total score between time points at baseline and end of week 4.

  3. Electroencephalogram (EEG) Assessment

    Time frame: Four weeks.

    Changes in electroencephalogram (EEG) will be assessed at baseline, week 2 and end of week 4.

Secondary outcomes

  1. Rivermead Post Concussion Symptoms Questionnaire (RPQ)

    Time frame: Four weeks.

    Changes in Rivermead Post Concussion Symptoms Questionnaire (RPQ); arithmetic changes in Rivermead Post-Concussion Symptoms Questionnaire (RPQ-16) total score between time points at baseline and end of week 4.

Other outcomes

  1. Safety Outcomes assessed by Arithmetic number of Adverse Events (AEs) and Serious Adverse Events (SAEs).

    Time frame: Four weeks.

    Arithmetic number of Adverse Events (AEs) and Serious Adverse Events (SAEs).

Sponsors and collaborators

Lead sponsor

Wave Neuroscience

Industry

Registry information

Official study title

A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With Attention Deficit Hyperactivity Disorder.

Acronym: MeRT-USC-009

Important dates

Study start
2016
Primary completion
2019
Study completion
2019
First posted
Feb 28, 2017
Registry last updated
Apr 19, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.